Figure 3.
![Comparison of clinical outcomes between patients treated on protocols 2012-0708 (with NK cells [blue line]) and 2009-0266 (no NK cells [red line]). Data from 2009-0266 were censored to include patients with only AML/MDS and CML in morphologic CR at the time of transplant. (A) Time to neutrophil engraftment. (B) Time to platelet engraftment. (C) Cumulative incidence of grade 2-4 acute GVHD. (D) Cumulative incidence of grade 3-4 aGVHD. (E) Cumulative incidence of chronic GVHD limited + extensive. (F) Incidence of BKV cystitis. (G) Incidence of CMV reactivation. (H) Cumulative incidence of relapse. (I) Probability of progression-free survival. Kaplan-Meier survival curves were compared using the log-rank method. BKV, BK polyomavirus.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/130/16/10.1182_blood-2017-05-785659/6/blood785659f3.jpeg?Expires=1720794329&Signature=B0lq62FZw57~XMCs4tP30wdg4duHrctb~A~UemYqktkqEzT-9nH61i8XXyC~AokuXP3SU~XpUBQb~M8XrhN9Ba36Q2bG~oMrOMWTP~C1C52RxlDiuryFSpnmmxMxK5eo57e6Xum2qCPtxltlOf8PYQfM8Yx4nsqp28fNqZpEJZZlsqP~1ICEZVEakpbK2QUWYibL-uH3ax7TG0jSVl38rPLFVbJuyhaMoj7jFpXNDpGYx5BhVpLYxu6P5b4r8SqP44WathjGOFkS5NFfy-oUW-WpTpDkaFAINDwyy45haZWXGiCzUq9Rdn8AQRugfN1trck3peewHp9jJIpZwmH~Jw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of clinical outcomes between patients treated on protocols 2012-0708 (with NK cells [blue line]) and 2009-0266 (no NK cells [red line]). Data from 2009-0266 were censored to include patients with only AML/MDS and CML in morphologic CR at the time of transplant. (A) Time to neutrophil engraftment. (B) Time to platelet engraftment. (C) Cumulative incidence of grade 2-4 acute GVHD. (D) Cumulative incidence of grade 3-4 aGVHD. (E) Cumulative incidence of chronic GVHD limited + extensive. (F) Incidence of BKV cystitis. (G) Incidence of CMV reactivation. (H) Cumulative incidence of relapse. (I) Probability of progression-free survival. Kaplan-Meier survival curves were compared using the log-rank method. BKV, BK polyomavirus.
